Aplastic Anemia Research Study
|
Alemtuzumab (Campath) for Refractory or Relapsed Severe Aplastic Anemia
|
Hematologists at the National Heart, Lung, and Blood Institute are investigating a new treatment for Severe Aplastic Anemia (SAA). The study drug, a monoclonal antibody, may help increase blood counts, reduce anemia symptoms, and/or reduce dependence on transfusions. Subjects will receive an intravenous infusion of study medication alemtuzumab (Campath) once a day for 10 days. Subjects will be admitted to the NIH Clinical Center hospital for study drug initiation. If the study drug infusion is tolerated well, the subject may be discharged and receive the remainder of the treatment course as an outpatient.
If you have been diagnosed with SAA and have received prior immunosuppressive therapy and have either failed to respond or have relapsed following treatment, you may be able to participate in this clinical trial. To find out if you qualify, please call our study coordinator at 301-496-4462 or email us at BloodStudy@nhlbi.nih.gov
|
|
 
|
|
|
|
Protocol Information |
|
|
|
Disease and Treatment Information |
|
|
|
Support Groups |
|
| |
|
|
Aplastic Anemia Research Study
|
Campath versus r-ATG/CsA versus h-ATG/CsA for previously untreated Severe Aplastic Anemia
|
Researchers at the National Heart, Lung, and Blood Institute of the National Institutes of Health, a part of the Department of Health and Human Services, are investigating methods of treatment for severe aplastic anemia. Hematologists are comparing the effectiveness of three immunosuppressive regimens in previously untreated (no prior immunosuppressive therapy) patients. The study may help increase blood counts, reduce anemia symptoms, and/or reduce dependence on immunosuppressive medications and transfusions. If determined eligible to participate, you (your child) will be selected by a process based on chance to receive one of threee therapies.
If you have been diagnosed with severe aplastic anemia and at least 2 years old, you (your child) may be able to participate in this clinical trial. To find out if you qualify, please call us toll free at 1-800-411-1222 (TTY 1-866-411-1010). Our email address is BloodStudy@nhlbi.nih.gov
|
|
|
|
|
|
Protocol Information |
|
|
|
Disease and Treatment Information |
|
|
|
Support Groups |
|
| |
|
|
Aplastic Anemia Research Study
|
Daclizumab for Aplastic Anemia
|
If you or someone you know has been diagnosed with aplastic anemia, you may be able to participate in a clinical trial evaluating a new immunosuppressive therapy. Hematologists are evaluating whether daclizumab, a genetically engineered human monoclonal antibody, can increase blood counts, reduce anemia symptoms, and/or reduce dependence on immunosuppressive medications and transfusions.
To find out if you qualify, please contact our research coordinator at (301) 594-4180 or email us at BloodStudy@nhlbi.nih.gov
|
|
|
|
|
|
Protocol Information |
|
|
|
Disease and Treatment Information |
|
|
|
Support Groups |
|
| |
|
|
Aplastic Anemia Research Study
|
Hepatitis-Associated Aplastic Anemia
|
Researchers at the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health (NIH), a part of the Department of Health and Human Services (DHHS) are conducting laboratory studies on blood, bone marrow, stool and/or liver tissue samples from subjects with hepatitis-associated aplastic anemia to improve our understanding of the disease and possibly identify one or more causative viral agents.
If you or someone you know has been diagnosed with hepatitis-associated aplastic anemia you may be able to participate in this clinical trial. To find out if you qualify, please contact our research coordinator at (301) 496-4462 or email us at BloodStudy@nhlbi.nih.gov
|
|
|
|
|
|
Protocol Information |
|
|
|
Disease and Treatment Information |
|
|
|
Support Groups |
|
| |
|
|
Aplastic Anemia Research Study
|
Randomized Trial of Campath versus r-ATG/CsA for Severe Aplastic Anemia
|
Researchers at the National Heart, Lung, and Blood Institute of the National Institutes of Health, a part of the Department of Health and Human Services, are investigating a new method of treatment for severe aplastic anemia. Hematologists are comparing the effectiveness of a new immunosuppressive treatment (Campath-1H) with rabbit ATG and Cyclosporine (CsA) therapy for patients with severe aplastic anemia. The study may help increase blood counts, reduce anemia symptoms, and/or reduce dependence on immunosuppressive medications and transfusions.
If you are determined eligible to participate, you will be selected by a process based on chance to receive either (1) Campath-1H for 10 days or (2) rabbit ATG for 5 days + CsA for 6 months.
If you have been diagnosed with severe aplastic anemia and are over the age of 14, you may be able to participate in this clinical trial. To find out if you qualify, please contact our coordinator at (301) 496-4462 or email us at BloodStudy@nhlbi.nih.gov
|
|
|
|
|
|
Protocol Information |
|
|
|
Disease and Treatment Information |
|
|
|
Support Groups |
|
| |
|
|
Aplastic Anemia Research Study
|
Rituximab (Rituxan) for Moderate Aplastic Anemia
|
If you or someone you know has been diagnosed with aplastic anemia you may be able to participate in a clinical trial evaluating a new immunosuppressive therapy. Hematologists are evaluating whether rituximab (Rituxan), a genetically engineered monoclonal antibody therapy, can increase blood counts, reduce anemia symptoms, and/or reduce dependence on immunosuppressive medications and transfusions. If you are determined eligible to participate, you will be treated with an infusion of rituximab once every week for a total of 4 doses and then followed to evaluate for response
To find out if you qualify, please contact our research coordinator at (301) 594-4180 or email us at BloodStudy@nhlbi.nih.gov
|
|
|
|
|
|
Protocol Information |
|
|
|
Disease and Treatment Information |
|
| |
|
|
Aplastic Anemia Research Study
|
Stem Cell Transplant for Patients with Aplastic Anemia
|
If you have been diagnosed with aplastic anemia or paroxysmal nocturnal hemoglobinuria (PNH), you may be able to participate in a stem cell transplant clinical trial designed to evaluate methods to decrease graft-versus-host disease, promote engraftment, and improve immune system recovery following a bone marrow stem cell transplant procedure.
You must have an HLA-matched family member to participate. You will be given chemotherapy followed by a transfusion of stem cells and lymphocytes from your donor, which will replace your immune system with the immune system of your healthy donor. Post-transplant therapy is designed to reduce the risk of graft-versus-host disease.
We do the blood testing free of charge to see if your family member is a match. We pay for all medical costs related to the transplant procedure. You must be available to live near NIH for approximately 3 months. We also provide a daily allowance to help with living expenses while you are on the study and living away from home.
To inquire about eligibility, contact our research coordinator (301) 594-8013 or by e-mail: BloodStudy@nhlbi.nih.gov
|
|
|
|
|
|
Protocol Information |
|
|
|
Disease and Treatment Information |
|
|
|
Support Groups |
|
| |
|
|
Autoimmune Thrombocytopenia (AITP) Research Study
|
GMA161 (anti-CD16) for Autoimmune Thrombocytopenia
|
If you or someone you know is 18 years old or older and has been diagnosed with autoimmune thrombocytopenia (ITP or AITP), you may be able to participate in a clinical trial evaluating a new therapy designed to decrease the destruction of platelets in the blood. Hematologists are evaluating whether GMA161, a genetically engineered human monoclonal antibody, may help temporarily increase platelet counts, reduce bleeding symptoms, and reduce or discontinue the need for immunosuppressive medications.
To find out if you qualify or for more information, please call our study coordinator at (301) 594-4180 or contact us at BloodStudy@nhlbi.nih.gov
|
|
|
|
|
|
Protocol Information |
|
|
|
Disease and Treatment Information |
|
|
|
Support Groups |
|
| |
|
|
Autoimmune Thrombocytopenia (AITP) Research Study
|
Treatment of Autoimmune Thrombocytopenia (AITP)
|
Platelets are particles found along with red and white blood cells in the blood that play a role in the process of blood clotting. Disorders affecting the platelets can lower the amount of platelets in the blood and put patients at risk of bleeding. The condition of low platelets is referred to as thrombocytopenia. Autoimmune thrombocytopenia (AITP) is a disorder of low blood platelet counts in which platelets are destroyed by antibodies produced by the immune system. Unfortunately, many patients with AITP do not respond to standard treatments for thrombocytopenia. Cyclophosphamide is a drug that works to suppress the activity of the immune system. We will combine this drug with transfusion of cells that form red and white blood cells and platelets (called stem cells) collected from the patient prior to this treatment.The purpose of this study is to explore the safety and effectiveness of this therapy for the treatment of AITP.
To inquire about eligibility, contact us by e-mail at
BloodStudy@nhlbi.nih.gov or call our research co-ordinator at 301-594-4180.
|
|
|
|
|
|
Protocol Information |
|
|
|
Support Groups |
|
| |
|
|
Cancer Research Study
|
Stem Cell Transplant for Treatment of Metastatic Renal Cell (Kidney) Cancer
|
If you have been diagnosed with metastatic renal cell (kidney) cancer, you may be eligible for a stem cell transplant procedure here at the National Institutes of Health (NIH). Under evaluation is whether graft-versus-tumor effects can be generated against renal cell tumors. You must have an HLA-matched family member to participate. You will be given chemotherapy followed by a transfusion of stem cells and lymphocytes from your donor which will replace your immune system with the immune system of your healthy donor. Post-transplant therapy is designed to reduce the risk of graft-versus-host disease.
We do the blood testing free of charge to see if your family member is a match. We pay for all medical costs related to the transplant procedure. You must be available to live near NIH for approximately 3 months. We also provide a daily allowance to help with living expenses while you are on the study and living away from home.
To inquire about eligibility, contact our research coordinator (301) 594-8013 or by e-mail: BloodStudy@nhlbi.nih.gov
|
|
|
|
|
|
Protocol Information |
|
|
|
Disease and Treatment Information |
|
| |
|
|
Cancer Research Study
|
Stem Cell Transplant for Treatment of Refractory Metastatic Cancers
|
Transplantation of cells from the bone marrow (called stem cells)that form blood cells and platelets is capable of curing patients with blood cancers such as acute and chronic leukemias. Powerful effects against cancer may be generated by specialized white blood cells from the donor, a process which is called graft-vs-leukemia or graft-vs-tumor. Recently, a similar graft-vs-solid tumor effect was demonstrated to occur in some patients with metastatic kidney cancer undergoing stem cell transplantation. This protocol is designed to test whether graft-vs-tumor effects can be generated against other types of solid tumors which have become resistant to standard therapy. Patients who have the following metastatic cancers: breast, bile ducts, small intestine, colon, rectal, esophageal, gastric, liver, pancreatic, prostate, or sarcomas, who have failed all standard treatment options and who have an HLA tissue-matched sibling or related family donor may be eligible for study enrollment. HLA typing can be performed for free on eligible patients and their family members by having blood samples mailed to the NIH.
The patient will be given chemotherapy followed by a transfusion of stem cells and lymphocytes from their donor. The procedure will replace the patients immune system with the immune system of the healthy donor.
Patients on this study live in the area for approximately four months. We pay for all medical costs related to the transplant, but the patient is responsible for living expenses while here. We provide an allowance to help with living expenses while the patient is here on study.
To inquire about eligibility, contact our research coordinator (301) 594-8013 or by e-mail: BloodStudy@nhlbi.nih.gov
|
|
|
|
|
|
Protocol Information |
|
|
|
Disease and Treatment Information |
|
| |
|
|
Diamond Blackfan Anemia / Inherited Bone Marrow Failure Syndromes Research Study
|
Daclizumab for Diamond Blackfan Anemia
|
If you or someone you know has been diagnosed with Diamond Blackfan Anemia, you may be able to participate in a clinical trial evaluating a new immunosuppressive therapy. Hematologists are evaluating whether daclizumab, a genetically engineered human monoclonal antibody, can increase blood counts, reduce anemia symptoms, and/or reduce dependence on immunosuppressive medications and transfusions.
To find out if you qualify, please contact our research coordinator at (301) 594-4180 or email us at BloodStudy@nhlbi.nih.gov
|
|
|
|
|
|
Protocol Information |
|
|
|
Disease and Treatment Information |
|
|
|
Support Groups |
|
| |
|
|
Diamond Blackfan Anemia / Inherited Bone Marrow Failure Syndromes Research Study
|
Rituximab (Rituxan) for Diamond-Blackfan Anemia
|
If you or your child has been diagnosed with Diamond Blackfan Anemia, you (your child) may be able to participate in a clinical trial evaluating a new immunosuppressive therapy. Hematologists are evaluating whether rituximab (Rituxan), a genetically engineered humanized monoclonal antibody therapy, may increase in the production of red blood cells by the bone marrow and thus a decrease in the number of transfusions needed to prevent symptoms of anemia.
To find out if you qualify, please contact our research coordinator at (301) 594-4180 or email us at BloodStudy@nhlbi.nih.gov
|
|
|
|
|
|
Protocol Information |
|
|
|
Disease and Treatment Information |
|
|
|
Support Groups |
|
| |
|
|
Diamond Blackfan Anemia / Inherited Bone Marrow Failure Syndromes Research Study
|
Stem Cell Transplant for Diamond Blackfan Anemia
|
If you (or someone you know) is between the ages of 16-65 years and have been diagnosed with Diamond Blackfan anemia, you may be eligible for a stem cell transplantation procedure at the Clinical Center of the National Institutes of Health (NIH). Under evaluation is the use of low-dose radiation and novel methods of transplant preparation and post transplant therapy to reduce the risk of graft-versus-host disease.
You must have an HLA-matched family member to participate. We will do the blood testing free of charge to see if your family member is a match. We pay for all medical costs related to the transplant procedure. You must be available to live near NIH for approximately four months. We also provide a small daily allowance to help with living expenses while you are on the study and living away from home.
For more information please contact our research coordinator at (301) 402-3087, or email us at BloodStudy@nhlbi.nih.gov
|
|
|
|
|
|
Protocol Information |
|
|
|
Disease and Treatment Information |
|
|
|
Support Groups |
|
| |
|
|
Leukemia Research Study
|
Imatinib for Chronic Leukemia
|
If you or someone you know is 18 years old or older and has been diagnosed with chronic myelomonocytic leukemia (CMML) or atypical chronic myelogenous leukemia (aCML), you may be able to participate in a clinical trial evaluating a new therapy. Imatinib has been shown to selectively kill leukemia cells in patients with chronic myeloid leukemia (CML). Hematologists are evaluating whether imatinib may help improve blood counts and/or reduce or discontinue the need for blood transfusions in these other forms of leukemia.
To find out if you qualify or for more information, please call our study coordinator at (301) 402-0797 or email BloodStudy@nhlbi.nih.gov
|
|
|
|
|
|
Protocol Information |
|
|
|
Disease and Treatment Information |
|
|
|
Support Groups |
|
| |
|
|
Leukemia Research Study
|
Lenalidomide (Revlimid) in CLL and SLL
|
Hematologists at the National Heart, Lung, and Blood Institute are investigating an experimental treatment for chronic lymphocytic leukemia (CLL) and small lymphocytic leukemia (SLL). The study drug--an immune modulator that may block blood vessel growth in cancers--may help normalize blood counts, reduce leukemia-related symptoms, decrease risk of infections and/or improve quality of life and long-term survival. Consenting subjects will take an oral dose of lenalidomide daily for 3 weeks and then no medication for 3 weeks and repeat the regimen 4 times (4 cycles). Response will be measured at 24 weeks. Responding patients will have the option to continue the regimen for 2 additional cycles (if in CR after 4 cycles) or 4 cycles (if in PR after 4 cycles).
If you have been diagnosed with CLL or SLL , have already been treated for CLL or SLL and are 21 years or older, you may be able to participate in this clinical trial. To find out if you qualify, please call our study coordinator at 301-402-0797 or email us atBloodStudy@nhlbi.nih.gov
|
|
|
|
|
|
Protocol Information |
|
|
|
Disease and Treatment Information |
|
|
|
Support Groups |
|
| |
|
|
Leukemia Research Study
|
Selectively Depleted Stem Cell Transplant to Treat Leukemia
|
If you or someone you know is diagnosed with ALL, AML, CLL, or CML, you may be able to participate in our clinical trial designed to investigate methods of making stem cell transplant procedures safer and more effective. Specifically, we are testing whether the special treatment of donor stem cells and immune cells will reduce complications (Graft versus host disease) and improve transplant outcome. You must have an HLA matched brother or sister who is willing to participate as a donor in order to participate in this study.
To find out if you qualify, please contact our research coordinator at (301) 496-3841 or by email at BloodStudy@nhlbi.nih.gov
|
|
|
|
|
|
Protocol Information |
|
|
|
Disease and Treatment Information |
|
|
|
Support Groups |
|
| |
|
|
Leukemia Research Study
|
Stem Cell Transplant and T Cell Add Back to Treat Leukemia
|
If you or someone you know is diagnosed with acute lymphocytic leukemia (ALL), acute myelogenous leukemia (AML), chronic lymphocytic leukemia (CLL), or chronic myrlogenous leukemia (CML), you may be able to participate in our clinical trial designed to investigate methods of making stem cell transplant procedures safer and more effective. Specifically, we are testing whether special treatment of donor stem cells and delaying the transfusion of donor immune cells will reduce complications and improve transplant outcome. You must have an HLA-matched brother or sister who is willing to participate as a donor in order to participate in this study.
To find out if you qualify, please contact our research coordinator at (301) 496-3841 or by email at BloodStudy@nhlbi.nih.gov
|
|
|
|
|
|
Protocol Information |
|
|
|
Disease and Treatment Information |
|
|
|
Support Groups |
|
| |
|
|
Leukemia Research Study
|
Stem Cell Transplant for High Risk Patients with Leukemia
|
If you have been diagnosed with ALL, AML, CLL, CML, or CMML you may be able to participate in a stem cell transplant clinical trial designed to evaluate methods to decrease graft-versus-host disease, promote engraftment, and improve immune system recovery following a bone marrow stem cell transplant procedure.
You must have an HLA-matched family member to participate. You will be given chemotherapy followed by a transfusion of stem cells and lymphocytes from your donor, which will replace your immune system with the immune system of your healthy donor. Post-transplant therapy is designed to reduce the risk of graft-versus-host disease.
We do the blood testing free of charge to see if your family member is a match. We pay for all medical costs related to the transplant procedure. You must be available to live near NIH for approximately 3 months. We also provide a daily allowance to help with living expenses while you are on the study and living away from home.
To inquire about eligibility, contact our research coordinator (301) 594-8013 or by e-mail: BloodStudy@nhlbi.nih.gov
|
|
|
|
|
|
Protocol Information |
|
|
|
Disease and Treatment Information |
|
|
|
Support Groups |
|
| |
|
|
Leukemia Research Study
|
Subcutaneous Rituximab (Rituxan) in Chronic Lymphocytic Leukemia (CLL)
|
Hematologists at the National Heart, Lung, and Blood Institute are investigating a new treatment for Chronic Lymphocytic Leukemia (CLL). The study drug, a monoclonal antibody, may help normalize blood counts, reduce leukemia related symptoms, decrease risk of infections and/or improve quality of life and long term survival. Consenting subjects will receive one intravenous infusion of study medication Rituximab (Rituxan) at the NIH Clinical Center followed by self-administered injections under the skin of the same drug 3 times a week for 12 weeks at home.
If you have been diagnosed with CLL, have already been treated with fludarabine and are 18 years or older, you may be able to participate in this clinical trial. To find out if you qualify, please call our study coordinator at 301-402-0797 or email us at BloodStudy@nhlbi.nih.gov
|
|
|
|
|
|
Protocol Information |
|
|
|
Disease and Treatment Information |
|
| |
|
|
Leukemia Research Study
|
WT1 +PR1 peptide vaccination for AML or CML
|
If you are 18 years old or older and have been diagnosed with AML or CML, you may be able to participate in a clinical trial evaluating a new therapy. We believe your immune system might be able to control the abnormal growth of cells that is causing your leukemia. This study will test whether vaccination with a WT1 peptide and a PR1 peptide may increase the number of immune cells responding to your leukemia and thereby slow progression of your illness, improve blood counts, reduce the need for transfusions of blood and platelets, or even achieve a remission for your leukemia Consenting subjects will receive one dose of WT1 vaccine and one dose of PR1 vaccine every other week for 12 weeks (total of 6 vaccinations) followed by post vaccination evaluations 2 weeks and 4 weeks after the last dose of the vaccines.
To find out if you qualify or for more information, please contact or study coordinator at 301-496-3841 or email us at BloodStudy@nhlbi.nih.gov
|
|
|
|
|
|
Protocol Information |
|
|
|
Disease and Treatment Information |
|
|
|
Support Groups |
|
| |
|
|
Leukemia Research Study
|
WT1 peptide vaccination study for Leukemia (AML, ALL, CML or CMML)
|
If you are 18 years old or older and have been diagnosed with AML, ALL, CML or CMML, you may be able to participate in a clinical trial evaluating a new therapy. We believe your immune system might be able to control the abnormal growth of cells that is causing your leukemia. This study will test whether vaccination with a WT-1 peptide may increase the number of immune cells responding to your leukemia and thereby slow progression of your illness, improve blood counts, reduce the need for transfusions of blood and platelets, or even achieve a remission for your leukemia. Consenting subjects will receive two intravenous infusion of fludarabine followed by 9 weekly vaccinations with a WT1 peptide followed by monthly follow up evaluations.
To find out if you qualify or for more information, please contact the study coordinator at 301-496-3841or email us at BloodStudy@nhlbi.nih.gov
|
|
|
|
|
|
Protocol Information |
|
|
|
Disease and Treatment Information |
|
|
|
Support Groups |
|
| |
|
|
Lymphoma Research Study
|
Alemtuzumab (Campath) for T-LGL Lymphoproliferative Disorders
|
Hematologists at the National Heart, Lung, and Blood Institute are investigating a new treatment for T-Large Granular Lymphocyte (T-LGL) Lymphoproliferative Disorders. The study drug, a monoclonal antibody, may help increase blood counts and reduce the number of abnormal T cell large granular lymphocytes. If eligible to participate, consenting subjects will receive an intravenous infusion of study medication alemtuzumab (Campath) once a day for 10 days. Subjects will be admitted to the NIH Clinical Center hospital for study drug initiation. If the study drug infusion is tolerated well, the subject may be discharged and receive the remainder of the treatment course as an outpatient.
If you have been diagnosed with T-LGL and are 18 years or older, you may be able to participate in this clinical trial. To find out if you qualify, please call our study coordinator at 301-496-4462 or email us at BloodStudy@nhlbi.nih.gov
|
|
|
|
|
|
Protocol Information |
|
|
|
Disease and Treatment Information |
|
| |
|
|
Lymphoma Research Study
|
Selectively Depleted Stem Cell Transplant to Treat Lymphoma
|
If you or someone you know is diagnosed with Non- Hodgkin's lymphoma or Mantle cell lymphoma, you may be able to participate in our clinical trial designed to investigate methods of making stem cell transplant procedures safer and more effective. Specifically, we are testing whether the special treatment of donor stem cells and immune cells will reduce complications (Graft versus host disease) and improve transplant outcome. You must have an HLA matched brother or sister who is willing to participate as a donor in order to participate in this study.
To find out if you qualify, please contact our research coordinator at (301) 496-3841 or by email at BloodStudy@nhlbi.nih.gov
|
|
|
|
|
|
Protocol Information |
|
|
|
Disease and Treatment Information |
|
|
|
Support Groups |
|
| |
|
|
Lymphoma Research Study
|
Stem Cell Transplant to Treat Lymphoma
|
If you or someone you know is diagnosed with Non- Hodgkin's lymphoma or Mantle Cell lymphoma, you may be able to participate in our clinical trial designed to investigate methods of making stem cell transplant procedures safer and more effective. Specifically, we are testing whether special treatment of donor stem cells and delaying the transfusion of donor immune cells will reduce complications and improve transplant outcome. You must have an HLA-matched brother or sister who is willing to participate as a donor in order to participate in this study.
To find out if you qualify, please contact our research coordinator at (301) 496-3841 or by email at BloodStudy@nhlbi.nih.gov
|
|
|
|
|
|
Protocol Information |
|
|
|
Disease and Treatment Information |
|
|
|
Support Groups |
|
| |
|
|
Lymphoma Research Study
|
Stem Cell Transplant and T-Cell Add Back to Treat Lymphoma
|
If you (or someone you know) have been diagnosed with Non- Hodgkin's lymphoma or Mantle cell lymphoma, you may be able to participate in our clinical trial designed to decrease graft-versus- host disease, promote engraftment, and improve immune system recovery following a bone marrow stem cell transplant. Specifically, we are testing whether special treatment of your donor's transplant cells and delaying the transfusion of donor lymphocytes (immune cells) will reduce complications and improve transplant outcome. You must have an HLA-matched brother or sister donor to participate in this trial.
To find out if you qualify, please contact our research coordinator at (301) 496-3841 or email us at BloodStudy@nhlbi.nih.gov
|
|
|
|
|
|
Protocol Information |
|
|
|
Disease and Treatment Information |
|
|
|
Support Groups |
|
| |
|
|
Lymphoma Research Study
|
Stem Cell Transplant for High Risk Patients with Lymphoma
|
If you have been diagnosed with Non-Hodgkin's lymphoma or Hodgkin's Disease you may be able to participate in a stem cell transplant clinical trial designed to evaluate methods to decrease graft-versus-host disease, promote engraftment, and improve immune system recovery following a bone marrow stem cell transplant procedure.
You must have an HLA-matched family member to participate. You will be given chemotherapy followed by a transfusion of stem cells and lymphocytes from your donor, which will replace your immune system with the immune system of your healthy donor. Post-transplant therapy is designed to reduce the risk of graft- versus-host disease.
We do the blood testing free of charge to see if your family member is a match. We pay for all medical costs related to the transplant procedure. You must be available to live near NIH for approximately 3 months. We also provide a daily allowance to help with living expenses while you are on the study and living away from home.
To inquire about eligibility, contact our research coordinator (301) 594-8013 or by e-mail: BloodStudy@nhlbi.nih.gov
|
|
|
|
|
|
Protocol Information |
|
|
|
Disease and Treatment Information |
|
|
|
Support Groups |
|
| |
|
|
Multiple Myeloma Research Study
|
Selectively Depleted Stem Cell Transplant to Treat Multiple Myeloma
|
If you (or someone you know) have been diagnosed with Multiple Myeloma or Waldenstrom's macroglobulinemia, you may be able to participate in our clinical trial designed to investigate methods of making stem cell transplant procedures safer and more effective. Specifically, we are testing whether the special treatment of donor stem cells and immune cells will reduce complications (Graft versus host disease) and improve transplant outcome. You must have an HLA matched brother or sister who is willing to participate as a donor in order to participate in this study.
To find out if you qualify, please contact our research coordinator at (301) 496-3841 or by email at BloodStudy@nhlbi.nih.gov
|
|
|
|
|
|
Protocol Information |
|
| | |
|
